Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis. Issue 12 (16th August 2017)

• Record Type: Journal Article
• Authors: Jonsson, Maria Karolina; Sundlisæter, Nina Paulshus; Nordal, Hilde Haugedal; Hammer, Hilde Berner; Aga, Anna-Birgitte; Olsen, Inge Christoffer; Brokstad, Karl Albert; van der Heijde, Désirée; Kvien, Tore K; Fevang, Bjørg-Tilde Svanes; Lillegraven, Siri; Haavardsholm, Espen A
• Is Part Of: Annals of the rheumatic diseases. Volume 76:Issue 12(2017)
• Page Start: 2031
• Page End: 2037
• Publication Date: 2017-08-16
• Subjects: early rheumatoid arthritis -- inflammation -- ultrasonography; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-211695
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Calprotectin is an inflammatory marker of interest in rheumatoid arthritis (RA). We evaluated whether the level of calprotectin was associated with disease activity, and if it was predictive of treatment response and radiographic progression in patients with early RA. Methods: Plasma from disease-modifying antirheumatic drug (DMARD)-naïve patients with RA fulfilling 2010 American College of Rheumatology/European League Against Rheumatism classification criteria with symptom duration <2 years was analysed for calprotectin at baseline, and after 1, 3 and 12 months. All patients received treat-to-target therapy, as part of a randomised controlled strategy trial (ARCTIC). The association between calprotectin, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) and measures of disease activity were assessed by correlations. We used likelihood ratios and logistic regression models to assess the predictive value of the baseline inflammatory markers for treatment response and radiographic damage. Results: 215 patients were included: 61% female, 82% anti-citrullinated peptide antibody positive, mean (SD) age 50.9 (13.7) years and median (25, 75 percentile) symptom duration 5.8 (2.8, 10.5) months. Calprotectin was significantly correlated with Clinical Disease Activity Index (r=0.32), ESR (r=0.50) and ultrasonography power Doppler (r=0.42) before treatment onset. After 12 months of treatment, calprotectin, but not ESR and CRP, was significantly correlated with power Doppler (r=0.27). Baseline levels of calprotectin, ESR and CRP were not predictive of treatment response, but high levels of calprotectin were associated with radiographic progression in multivariate models. Conclusions: Calprotectin was correlated with inflammation assessed by ultrasound before and during DMARD treatment, and was also associated with radiographic progression. The data support that calprotectin may be of interest as an inflammatory marker when assessing disease activity in different stages of RA. Trial registration number: NCT01205854; Post-results.